Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. This is an ASCO Meeting Abstract from the 2016 ASCO Annual ...
Author(s)Goldschmidt H, Moreau P, Ludwig H, et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ...
Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX). This is an ASCO Meeting ...
The IMiD lenalidomide has shown promising results as a single agent 16 as well as in combination with other active agents for the treatment of MM. 15, 17, 18, 19, 20 ...
A dexamethasone-sparing regimen involving lenalidomide (Revlimid) and the anti-CD38 drug daratumumab (Darzalex) was safe and effective in older, frail patients with newly diagnosed multiple myeloma, ...
Alfred L. Garfall, MD, discusses follow-up data from the DREAMM-8 study presented at ASCO 2024. Please provide your key takeaways from this study.How might these findings impact the management of ...
A full study testing dexamethasone — a cheap, widely available steroid — as a treatment for COVID-19 found that the drug reduced mortality rates among patients on ventilators or who were receiving ...
A British trial showing that a common steroid could reduce deaths in severe COVID-19 cases by one-third was good news for Minnesota physicians who have been battling the infectious disease without a ...
A dexamethasone-sparing regimen of daratumumab and lenalidomide was safe and effective in older, frail patients with newly diagnosed multiple myeloma. Among that select group of patients, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results